Literature DB >> 29524596

The neurochemistry of agitation in Alzheimer's disease: a systematic review.

Kathy Y Liu1, Aisling E Stringer2, Suzanne J Reeves2, Robert J Howard2.   

Abstract

OBJECTIVE: To provide an up-to-date systematic review of the characteristics, methodology and findings of studies that have investigated the neurochemistry of agitation in Alzheimer's disease (AD).
METHODS: Electronic databases were searched for published peer-reviewed articles which provided data on any neurotransmitter system in relation to agitation in AD. Screening of titles and abstracts and data extraction from full texts were conducted in duplicate.
RESULTS: Forty-five studies were included. Monoamines (serotonin, dopamine and noradrenaline) were most commonly investigated. A variety of methods were used to investigate the neurochemistry underlying agitation in AD and, although there were several conflicting findings, there was evidence of serotonergic deficit, relatively preserved dopaminergic function and compensatory overactivity of postsynaptic noradrenergic neurons in agitation in AD.
CONCLUSIONS: Disruption of the dynamic balance between multiple neurotransmitter systems could impair functional neural networks involved in affective regulation and executive function. Differences in study design and methodology may have contributed to conflicting findings. Future studies that overcome these limitations (e.g. using standardized criteria to define agitation) and employ neuroimaging methods such as MRI/PET to investigate specific neural networks are needed to clarify the role of neurotransmitter alterations in these patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Agitation; Alzheimer’s disease; Monoamines; Neurotransmitters

Mesh:

Substances:

Year:  2018        PMID: 29524596     DOI: 10.1016/j.arr.2018.03.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  11 in total

1.  Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease.

Authors:  Clifford M Cassidy; Joseph Therriault; Tharick A Pascoal; Victoria Cheung; Melissa Savard; Lauri Tuominen; Mira Chamoun; Adelina McCall; Seyda Celebi; Firoza Lussier; Gassan Massarweh; Jean-Paul Soucy; David Weinshenker; Christine Tardif; Zahinoor Ismail; Serge Gauthier; Pedro Rosa-Neto
Journal:  Neuropsychopharmacology       Date:  2022-02-17       Impact factor: 8.294

2.  Comparing Behavioral and Psychological Symptoms of Dementia and Caregiver Distress Caused Between Older Adults With Dementia Living in the Community and in Nursing Homes.

Authors:  Xuejiao Lu; Rui Ye; Jialan Wu; Dongping Rao; Xiaoyan Liao
Journal:  Front Psychiatry       Date:  2022-05-16       Impact factor: 5.435

3.  Neuropsychological decline up to 20 years before incident mild cognitive impairment.

Authors:  Richard J Caselli; Blake T Langlais; Amylou C Dueck; Yinghua Chen; Yi Su; Dona E C Locke; Bryan K Woodruff; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2020-01-06       Impact factor: 21.566

4.  The Relationship Between Anxiety and Incident Agitation in Alzheimer's Disease.

Authors:  Kathy Y Liu; Harry Costello; Suzanne Reeves; Robert Howard
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity.

Authors:  Zhisheng Mi; Bing Gan; Sihang Yu; Jianan Guo; Changjun Zhang; Xiaoying Jiang; Tao Zhou; Jing Su; Renren Bai; Yuanyuan Xie
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 6.  Potential of Caffeine in Alzheimer's Disease-A Review of Experimental Studies.

Authors:  Piotr Londzin; Milena Zamora; Beata Kąkol; Aleksandra Taborek; Joanna Folwarczna
Journal:  Nutrients       Date:  2021-02-06       Impact factor: 5.717

Review 7.  Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.

Authors:  Claudia Carrarini; Mirella Russo; Fedele Dono; Filomena Barbone; Marianna G Rispoli; Laura Ferri; Martina Di Pietro; Anna Digiovanni; Paola Ajdinaj; Rino Speranza; Alberto Granzotto; Valerio Frazzini; Astrid Thomas; Andrea Pilotto; Alessandro Padovani; Marco Onofrj; Stefano L Sensi; Laura Bonanni
Journal:  Front Neurol       Date:  2021-04-16       Impact factor: 4.003

8.  Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.

Authors:  Michael C B David; Martina Del Giovane; Kathy Y Liu; Benjamin Gostick; James Benedict Rowe; Imafidon Oboh; Robert Howard; Paresh A Malhotra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-07-05       Impact factor: 13.654

9.  Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).

Authors:  Esther S Oh; Paul B Rosenberg; Gail B Rattinger; Elizabeth A Stuart; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos
Journal:  J Am Geriatr Soc       Date:  2020-12-31       Impact factor: 5.562

10.  Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.

Authors:  Christoph Mueller; Christeena John; Gayan Perera; Dag Aarsland; Clive Ballard; Robert Stewart
Journal:  Eur J Epidemiol       Date:  2020-05-15       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.